福元医药: 北京福元医药股份有限公司关于股票交易异常波动的公告

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative increase of 20% over three consecutive trading days, prompting an announcement regarding abnormal trading conditions [1][2]. Group 1: Stock Trading Abnormalities - The company's stock price increased by 20% over three consecutive trading days: July 31, August 1, and August 4, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [1]. - The company conducted a self-examination and confirmed that there are no undisclosed significant matters related to the stock price fluctuation, as verified with the controlling shareholder and actual controller [1][2]. Group 2: Business Operations - The company's management confirmed that production and operational activities are normal, with no significant changes in the internal or external environment [2]. - There are no undisclosed major matters related to asset restructuring, share issuance, or other significant transactions that could impact the company [2]. Group 3: Market Sentiment and Media Reports - The company noted increased market attention on its innovative drug business, particularly following the announcement of receiving clinical trial approval on April 9, 2025, although the project is still in Phase I clinical trials with significant uncertainties regarding its success [2]. - No other media reports or market rumors have been identified that could significantly impact the company's stock price [2]. Group 4: Board Confirmation - The board of directors confirmed that there are no undisclosed matters that should have been reported according to the Shanghai Stock Exchange rules, and previous disclosures do not require correction or supplementation [4].